Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients

This study has been completed.
Sponsor:
Collaborator:
Merck Frosst Canada Ltd.
Information provided by (Responsible Party):
Alexandra Papaioannou, McMaster University
ClinicalTrials.gov Identifier:
NCT00424619
First received: January 17, 2007
Last updated: May 11, 2012
Last verified: May 2012
Results First Received: July 25, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Condition: Hip Fracture
Interventions: Drug: Vitamin D2
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
50 000 IU Vitamin D2 50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
100 000 IU Vitamin D2 100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
Placebo Placebo at beginning of study and 1000IU vitamin D3 for 90 days

Participant Flow for 3 periods

Period 1:   Baseline
    50 000 IU Vitamin D2     100 000 IU Vitamin D2     Placebo  
STARTED     22     22     21 [1]
COMPLETED     22     22     20  
NOT COMPLETED     0     0     1  
[1] n=21 but one participant was lost as a screen failure

Period 2:   4 Week
    50 000 IU Vitamin D2     100 000 IU Vitamin D2     Placebo  
STARTED     18     17     17  
COMPLETED     18     17     17  
NOT COMPLETED     0     0     0  

Period 3:   3 Month
    50 000 IU Vitamin D2     100 000 IU Vitamin D2     Placebo  
STARTED     12     18     17  
COMPLETED     12     18     17  
NOT COMPLETED     0     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
50 000 IU Vitamin D2 50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
100 000 IU Vitamin D2 100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
Placebo Placebo at beginning of study and 1000IU vitamin D3 for 90 days
Total Total of all reporting groups

Baseline Measures
    50 000 IU Vitamin D2     100 000 IU Vitamin D2     Placebo     Total  
Number of Participants  
[units: participants]
  22     22     20     64  
Age  
[units: years]
Mean ± Standard Deviation
  82.9  ± 8.7     73.9  ± 12.4     78.5  ± 10.3     78.43  ± 11.09  
Gender  
[units: participants]
       
Female     15     8     13     36  
Male     7     14     7     28  
Region of Enrollment  
[units: participants]
       
Canada     22     22     20     64  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   25-hydroxyvitamin D3 (25-OHD)   [ Time Frame: Baseline, 4 weeks and 3 months ]

2.  Primary:   Parathyroid Hormone (PTH)   [ Time Frame: Baseline ]

3.  Primary:   Calcium   [ Time Frame: Baseline, 4 weeks ]

4.  Primary:   Phosphate   [ Time Frame: Baseline ]

5.  Primary:   Alkaline Phosphatase   [ Time Frame: Baseline ]
  Hide Outcome Measure 5

Measure Type Primary
Measure Title Alkaline Phosphatase
Measure Description Baseline blood samples were drawn in-hospital. In additional Alkaline Phosphatase was accessed at baseline.
Time Frame Baseline  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
50 000 IU Vitamin D2 50 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
100 000 IU Vitamin D2 100 000 IU Vitamin D2 at beginning of study and 1000IU vitamin D3 for 90 days
Placebo Placebo at beginning of study and 1000IU vitamin D3 for 90 days

Measured Values
    50 000 IU Vitamin D2     100 000 IU Vitamin D2     Placebo  
Number of Participants Analyzed  
[units: participants]
  22     22     20  
Alkaline Phosphatase  
[units: U/L]
Mean ± Standard Deviation
  98.6  ± 3.78     78.7  ± 26.2     79.4  ± 51.1  

No statistical analysis provided for Alkaline Phosphatase



6.  Primary:   Hemoglobin   [ Time Frame: Baseline ]

7.  Primary:   Creatinine   [ Time Frame: Baseline ]

8.  Secondary:   Functional Assessment Using the Timed Up and Go (TUG) Test After 3 Months   [ Time Frame: 3 months ]

9.  Secondary:   Functional Assessment Using the Two Minute Walk Test (2MWT)After 3 Months   [ Time Frame: 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information